Enliven Therapeutics, Inc. (ELVN)
NASDAQ:ELVN
Want to see ELVN full AI Analyst Report?
Top Page
Enliven Therapeutics
(NASDAQ:ELVN)
Select Model
Select Model
Rating:56Neutral
Price Target:
$44.00
▼(-8.54% Downside)
Action:Reiterated
Date:06/16/26
The score is driven by a strong balance sheet and supportive recent pipeline/financing events, partly offset by the company’s pre-revenue status with large ongoing losses and cash burn. Technical signals are neutral, while valuation is constrained by negative earnings and no dividend support.
Positive Factors
Strong balance sheet
Enliven's minimal leverage and a materially larger equity base provide durable financial flexibility to fund clinical programs without immediate debt pressure. A strong capital base supports multi-year R&D spending, improves partner negotiating leverage, and reduces near-term insolvency risk while trials advance.
Negative Factors
Pre-revenue with widening operating losses
Enliven remains without product revenue while operating losses have widened materially over recent years. Persisting negative profitability means the company must convert clinical success into commercial revenue or viable licensing deals to generate returns, otherwise investor dilution and strategic trade-offs are likely.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
Enliven's minimal leverage and a materially larger equity base provide durable financial flexibility to fund clinical programs without immediate debt pressure. A strong capital base supports multi-year R&D spending, improves partner negotiating leverage, and reduces near-term insolvency risk while trials advance.
Read all positive factors
Enliven Therapeutics (ELVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.22B
Dividend YieldN/A
Average Volume (3M)1.31M
Price to Earnings (P/E)―
Beta (1Y)1.03
Revenue GrowthN/A
EPS Growth13.79%
CountryUS
Employees62
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.64
Shares Outstanding71,438,280
10 Day Avg. Volume2,513,981
30 Day Avg. Volume1,311,378
Financial Highlights & Ratios
PEG Ratio2.65
Price to Book (P/B)1.90
Price to Sales (P/S)0.00
P/FCF Ratio-12.38
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-43.34K
Enterprise Value/Ebitda-26.38
Forecast
1Y Price Target
$59.56Price Target Upside23.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.75
Revenue Forecast (FY)N/A
Enliven Therapeutics Business Overview & Revenue Model
Company Description
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small ...
How the Company Makes Money
As a clinical-stage biotechnology company, Enliven Therapeutics does not have recurring revenue from commercial drug sales unless and until a product is approved and launched. Its ability to generate revenue is primarily tied to strategic transact...
Enliven Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -60.00K | -263.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -98.57M | -103.43M | -88.47M | -71.29M | -37.45M | -24.63M |
| Net Income | -98.78M | -103.69M | -89.02M | -71.58M | -37.66M | -24.74M |
Balance Sheet | ||||||
| Total Assets | 464.85M | 476.17M | 325.76M | 271.87M | 83.30M | 113.33M |
| Cash, Cash Equivalents and Short-Term Investments | 452.40M | 462.62M | 313.44M | 253.15M | 75.54M | 110.02M |
| Total Debt | 302.00K | 399.00K | 0.00 | 335.00K | 323.00K | 159.00K |
| Total Liabilities | 11.49M | 16.68M | 15.91M | 25.96M | 160.12M | 6.47M |
| Stockholders Equity | 453.37M | 459.60M | 309.85M | 245.91M | -76.83M | 106.86M |
Cash Flow | ||||||
| Free Cash Flow | -65.60M | -70.46M | -73.24M | -61.42M | -32.69M | -19.32M |
| Operating Cash Flow | -65.47M | -70.30M | -73.19M | -61.27M | -32.08M | -19.13M |
| Investing Cash Flow | -132.74M | -173.84M | -36.00M | -148.41M | -612.00K | -191.00K |
| Financing Cash Flow | 228.69M | 218.87M | 133.16M | 234.29M | -1.80M | -1.02M |
Enliven Therapeutics Technical Analysis
Positive
48.11
Price Trends
41.75
Positive
36.07
Positive
28.23
Positive
Market Momentum
0.82
Negative
60.93
Neutral
77.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELVN, the sentiment is Positive. The current price of 48.11 is above the 20-day moving average (MA) of 39.77, above the 50-day MA of 41.75, and above the 200-day MA of 28.23, indicating a bullish trend. The MACD of 0.82 indicates Negative momentum. The RSI at 60.93 is Neutral, neither overbought nor oversold. The STOCH value of 77.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ELVN.
Enliven Therapeutics Risk Analysis
Enliven Therapeutics disclosed 89 risk factors in its most recent earnings report. Enliven Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Enliven Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $3.22B | -28.67 | -21.04% | ― | ― | 13.79% | |
54 Neutral | $1.85B | 28.29 | 4.89% | ― | -2.20% | 77.51% | |
53 Neutral | $2.19B | -4.71 | -57.27% | ― | 45.04% | 32.42% | |
53 Neutral | $1.69B | -11.64 | -14.86% | ― | 242.66% | 15.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.84B | -4.71 | -60.70% | ― | 23382.78% | 7.01% |
* Healthcare Sector Average
ELVN
Enliven Therapeutics
45.10
23.80
111.74%
SRPT
Sarepta Therapeutics
17.53
-2.55
-12.70%
VRDN
Viridian Therapeutics
16.63
1.91
12.98%
NTLA
Intellia Therapeutics
15.67
6.47
70.33%
ABCL
AbCellera Biologics
5.53
2.12
62.17%
Enliven Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Enliven Therapeutics Prices Upsized Public Equity Offering
Positive
Jun 12, 2026
On June 11, 2026, Enliven Therapeutics priced an upsized underwritten public offering of 8,933,334 shares of common stock at $37.50 per share and pre-funded warrants for 1,733,333 shares at $37.499 each, all sold by the company. The deal, which in...
Business Operations and StrategyProduct-Related Announcements
Enliven advances ELVN-001 with positive Phase 1 data
Positive
Jun 11, 2026
On June 11, 2026, Enliven reported updated positive Phase 1 data for ELVN-001 in previously treated CML patients, including heavily pretreated individuals, with a cutoff date of March 10, 2026 for efficacy and safety analyses. In the Phase 1b stud...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Enliven Therapeutics Expands Authorized Shares After Stockholder Vote
Positive
Jun 10, 2026
Enliven Therapeutics, Inc. held its Annual Meeting of Stockholders on June 9, 2026, where shareholders approved an amendment to the company’s certificate of incorporation to double its authorized common stock from 100,000,000 to 200,000,000 ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.